All sponsors

Novartis Pharmaceuticals $NVS

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS181
PHASE 3 / 2-389
RECRUITING78
READOUTS ≤12 MONTHS51
READOUT SLIPPED >6 MO42%

Delay Index: of 140 active trials registered more than a year ago, 59 have moved their primary completion (readout) date by more than 6 months since first registration (median +3.1 months). See all sponsors →

Open Novartis Pharmaceuticals on the live radar map → 📅 $NVS readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Interferon beta-1a
NCT01892722
P3Active, not recruitingMultiple Sclerosis2402017-07-14 (+7 mo)
inclisiran sodium
NCT04765657
P3Active, not recruitingHypercholesterolemia3452022-06-09 (-1 mo)
STAND
NCT03814746
P3Active, not recruitingSickle Cell Disease (SCD)2532022-08-31 (+3 mo)
MANIFEST-2
NCT04603495
P3Active, not recruitingMyelofibrosis; Primary Myelofibrosis4302023-08-23 (+12 mo)
Imatinib
NCT04971226
P3Active, not recruitingChronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive4052023-11-28 (-10 mo)
EPIK-P2
NCT04589650
P2Active, not recruitingPIK3CA-related Overgrowth Spectrum (PROS)2362024-03-20 (+14 mo)
AFFINITY
NCT04573920
P2Active, not recruitingIgA Nephropathy; Focal Segmental Glomerulosclerosis1032024-07-02 (+19 mo)
LOU064 (blinded)
NCT05513001
P3Active, not recruitingChronic Spontaneous Urticaria6962024-08-26 (-30 mo)
KontRASt-06
NCT05445843
P2Active, not recruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation952024-11-04 (-24 mo)
[177Lu]Lu-PSMA-617
NCT05658003
P2Active, not recruitingMetastatic Castration-Resistant Prostate Cancer (mCRPC)632024-12-02 (-23 mo)
PSMAddition
NCT04720157
P3Active, not recruitingProstatic Neoplasms11442025-01-13 (-29 mo)
Dabrafenib
NCT04940052
P3Active, not recruitingDifferentiated Thyroid Cancer (DTC)1532025-01-22 (+11 mo)
Ianalumab
NCT05885555
P2Active, not recruitingPrimary Immune Thrombocytopenia (ITP)412025-02-05 (+4 mo)
Eltrombopag
NCT04797000
P2Active, not recruitingMyelodysplastic Syndromes362025-04-26 (+33 mo)
NEPTUNUS-2
NCT05349214
P3Active, not recruitingSjogren Syndrome5062025-05-13 (-10 mo)
ASC4START
NCT05456191
P3Active, not recruitingPhiladelphia Chromosome-Positive Chronic Myeloid Leukemia5682025-05-15 (-21 mo)
VAYHIT2
NCT05653219
P3Active, not recruitingPrimary Immune Thrombocytopenia1522025-06-19
ASC2ESCALATE
NCT05384587
P2Active, not recruitingChronic Myelogenous Leukemia - Chronic Phase342025-08-13 (+5 mo)
Remibrutinib
NCT06042478
P3Active, not recruitingChronic Spontaneous Urticaria4702025-09-17 (+1 mo)
MASter-1
NCT04641442
P2Active, not recruitingNLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations172025-10-14 (+21 mo)
FILIOS
NCT06869785
P3Active, not recruitingRelapsing Multiple Sclerosis (RMS)1962026-01-28 (-11 mo)
VAY736 1ml PFS
NCT06293365
P2Active, not recruitingSjögrens Disease; Systemic Lupus Erythematosus1552026-02-17 (+5 mo)
VAYHIA
NCT05648968
P3Active, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)902026-02-20
NEOS
NCT04926818
P3Active, not recruitingMultiple Sclerosis (MS)1292026-03-25 (-6 mo)
Remibrutinib
NCT05976243
P3Active, not recruitingChronic Inducible Urticaria3622026-05-11 (-2 mo)
PLATINUM
NCT05750628
P2RecruitingUncomplicated Plasmodium Falciparum Malaria3272026-06-09 (+11 mo)
ASTRALS
NCT06643481
P2Active, not recruitingAmyotrophic Lateral Sclerosis (ALS)2512026-06-23 (-7 mo)
Remibrutinib
NCT05147220
P3Active, not recruitingRelapsing Multiple Sclerosis10002026-07-21 (+9 mo)
REMODEL-2
NCT05156281
P3Active, not recruitingRelapsing Multiple Sclerosis10072026-07-22 (+9 mo)
Saline
NCT06857955
P2Active, not recruitingHypertension3962026-09-17 (-3 mo)
V-PLAQUE
NCT05360446
P3Active, not recruitingCoronary Artery Disease6102026-10-26 (+17 mo)
VAYHIT1
NCT05653349
P3Active, not recruitingPrimary Immune Thrombocytopenia (ITP)2262026-10-29 (+13 mo)
LOU064 (blinded)
NCT05677451
P3Active, not recruitingChronic Spontaneous Urticaria1002026-11-03 (+14 mo)
AAA617
NCT06004661
P2Active, not recruitingMetastatic Castration-Resistant Prostate Cancer (mCRPC)232026-11-06 (+8 mo)
PSMAndARPI
NCT06894511
P2Active, not recruitingMetastatic Castration Resistant Prostate Cancer (mCRPC)72026-11-17 (-4 mo)
JSB462
NCT06991556
P2Active, not recruitingMetastatic Hormone-sensitive Prostate Cancer1682026-12-03 (-64 mo)
PSMACare
NCT05849298
P2Active, not recruitingProstatic Neoplasm492026-12-23 (-23 mo)
Iptacopan
NCT06388941
P2Active, not recruitingAnti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis842026-12-30 (-8 mo)
ACS
NCT07102628
P3Active, not recruitingAcute Coronary Syndrome3052027-01-16 (-2 mo)
KontRASt-01
NCT04699188
P1/2Active, not recruitingKRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small-Cell Lung3442027-01-25 (+35 mo)
EPIK-B5
NCT05038735
P3Active, not recruitingBreast Cancer2102027-01-28 (+3 mo)
Alpelisib
NCT04544189
P2Active, not recruitingBreast Neoplasms692027-01-29 (+39 mo)
APPEAR-C3G
NCT04817618
P3RecruitingC3G982027-01-29 (+42 mo)
LEE011
NCT02934568
P2Active, not recruitingContinued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies222027-02-01 (+58 mo)
LXH254
NCT04417621
P2Active, not recruitingMelanoma1342027-02-02 (+45 mo)
PLATINUM
NCT07811908
P2RecruitingUncomplicated Plasmodium Falciparum Malaria1202027-02-04
RECLAIM
NCT06868212
P3Active, not recruitingChronic Spontaneous Urticaria (CSU)4092027-02-22
EPIK-B2
NCT04208178
P3Active, not recruitingAdvanced HER2+Breast Cancer192027-02-26 (+35 mo)
everolimus
NCT02962414
P3Active, not recruitingTuberous Sclerosis Complex2062027-02-26
Alpelisib
NCT04524000
P2Active, not recruitingAdvanced Breast Cancer242027-02-26 (+44 mo)
LEE011
NCT01872260
P1/2Active, not recruitingBreast Cancer2592027-02-26
CRYPTONITE
NCT07249463
P2RecruitingCryptosporidiosis802027-03-23
SIRIUS-SLE 1
NCT05639114
P3Active, not recruitingSystemic Lupus Erythematosus4362027-03-26 (+2 mo)
CTL019
NCT04094311
P3RecruitingB-cell Acute Lymphoblastic Leukemia; Diffuse Large B-cell Lymphoma2002027-03-31 (+60 mo)
SIRIUS-SLE 2
NCT05624749
P3Active, not recruitingSystemic Lupus Erythematosus2882027-04-12 (+2 mo)
NeoB-Cap1
NCT06247995
P1/2Active, not recruitingBreast Cancer202027-04-14 (-53 mo)
MAS825
NCT07203001
P2RecruitingStill´s Disease302027-04-22 (-24 mo)
DII235
NCT07235046
P2Active, not recruitingLipoprotein Disorder2342027-04-26
QCZ484
NCT07610278
P2RecruitingHypercholesterolaemia1202027-04-28
Iptacopan
NCT06517758
P3Active, not recruitingGeneralized Myasthenia Gravis1462027-04-30 (+4 mo)
VICTORION-2P
NCT05030428
P3Active, not recruitingAtherosclerotic Cardiovascular Disease170042027-05-10 (+4 mo)
Remibrutinib Dose A
NCT06799000
P3Active, not recruitingHidradenitis Suppurativa5882027-05-17 (-16 mo)
GIA632
NCT07220577
P2Active, not recruitingAtopic Dermatitis342027-05-17
ARV-766
NCT05067140
P1/2Active, not recruitingProstate Cancer Metastatic1642027-05-25 (+30 mo)
RECHARGE-2
NCT06840392
P3Active, not recruitingHidradenitis Suppurativa5652027-06-03 (-12 mo)
EPIK-P3
NCT04980833
P2Active, not recruitingPIK3CA-related Overgrowth Spectrum (PROS)412027-06-22 (-4 mo)
Rapcabtagene autoleucel single agent
NCT03960840
P1/2Active, not recruitingChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma2182027-06-30 (+55 mo)
JSB462
NCT07047118
P2Active, not recruitingProstatic Cancer, Castration-Resistant1382027-07-16 (-7 mo)
EYU688
NCT06006559
P2RecruitingDengue1082027-07-22 (+33 mo)
LXE408
NCT06632600
P2RecruitingChagas Disease1302027-07-22
STAR-1
NCT07467993
P2RecruitingSchizophrenia1422027-07-29
Glycopyrronium bromide 25ug
NCT05222529
P2RecruitingAsthma422027-07-30 (+42 mo)
Ianalumab
NCT06470048
P2Active, not recruitingDiffuse Cutaneous Systemic Sclerosis2032027-07-30 (-11 mo)
Capmatinib
NCT03040973
P2Active, not recruitingAdvanced Solid Tumors Which Are cMET-dependent292027-07-30 (+100 mo)
BION-1301
NCT05852938
P3Active, not recruitingIgA Nephropathy; Immunoglobulin A Nephropathy3832027-08-10 (+13 mo)
YMI024
NCT07830719
P2RecruitingCoronary Artery Disease1802027-08-15
Remibrutinib
NCT06865651
P2RecruitingChronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)442027-08-23 (+2 mo)
Asciminib Pediatric formulation group
NCT04925479
P1/2Active, not recruitingMyeloid Leukemia, Philadelphia Positive462027-09-03 (+23 mo)
PKN605
NCT07217067
P2RecruitingAtrial Fibrillation1652027-09-09
SIRIUS-LN
NCT05126277
P3Active, not recruitingLupus Nephritis4522027-09-21 (+29 mo)
DYP688
NCT05415072
P1/2Active, not recruitingMetastatic Uveal Melanoma662027-10-01 (+23 mo)
Iptacopan
NCT04747613
P3Active, not recruitingParoxysmal Nocturnal Hemoglobinuria2082027-10-18 (+17 mo)
CASSIOPEIA
NCT03876769
P2Active, not recruitingB-Cell Acute Lymphoblastic Leukemia1212027-10-19 (+11 mo)
Iptacopan
NCT06797518
P2RecruitingGlomerulonephritis, IGA; Immunoglobulin A Nephropathy202027-11-27
LOU064
NCT07681271
P2RecruitingPapulopustular Rosacea1002027-12-07
LuMIERE
NCT04939610
P1/2RecruitingSolid Tumor2222027-12-31 (+42 mo)
QMF149
NCT05562466
P3RecruitingAsthma2002028-02-01 (+25 mo)
ADD-VANTAGE
NCT06813911
P3Active, not recruitingAtherosclerotic Cardiovascular Disease (ASCVD)2462028-02-03 (+5 mo)
decitabine
NCT05201066
P2Active, not recruitingMyelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic332028-02-14 (+2 mo)
rapcabtagene autoleucel
NCT06581198
P2Active, not recruitingLupus Erythematosus, Systemic; Lupus Nephritis1792028-02-14 (-16 mo)
RELIEVE
NCT06744920
P3Active, not recruitingGeneralized Myasthenia Gravis1802028-02-25
[177Lu]Lu-DOTA-TATE
NCT05142696
P1/2Active, not recruitingExtensive Stage Small Cell Lung Cancer552028-03-07 (+45 mo)
ORION-20
NCT06597019
P3RecruitingFamilial Hypercholesterolemia - Heterozygous602028-03-21
ORION-19
NCT06597006
P3RecruitingFamilial Hypercholesterolemia - Homozygous92028-03-21
ALIGN
NCT04573478
P3Active, not recruitingIgA Nephropathy; Immunoglobulin A Nephropathy4042028-04-14 (+52 mo)
PSMA-DC
NCT05939414
P3RecruitingOligometastatic Prostate Cancer (OMPC)4502028-04-25 (+23 mo)
ITU512
NCT06546670
P1/2RecruitingSickle Cell Disease1612028-05-01 (+6 mo)
REPLENISH-EXT
NCT06331312
P3Active, not recruitingPolymyalgia Rheumatica1622028-05-08 (+2 mo)
MANIFEST-3
NCT07357727
P3RecruitingPrimary Myelofibrosis (PMF); Post-polycythemia Vera Myelofibrosis (PPV-MF)4602028-05-17
Remibrutinib
NCT07816328
P3RecruitingChronic Spontaneous Urticaria3822028-05-24
EPIK-L1
NCT05948943
P2/3RecruitingLymphatic Malformations2322028-05-31 (-18 mo)
VITESS
NCT07431177
P2RecruitingNon-segmental Vitiligo2102028-06-06
PSMAcTION
NCT06780670
P2/3RecruitingProstate Cancer4432028-06-27 (+2 mo)
AMO959
NCT07226986
P1/2RecruitingPSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy1232028-07-10
Iptacopan
NCT05935215
P3RecruitingAtypical Hemolytic Uremic Syndrome502028-07-21 (-2 mo)
LEDA
NCT05888493
P3Active, not recruitingFollicular Lymphoma (FL)1092028-07-25 (+2 mo)
VHB937
NCT07094516
P2Active, not recruitingAlzheimer's Disease962028-09-14
LUMINA IgAN
NCT07850752
P3Not yet recruitingIgA Nephropathy (IgAN)3402028-09-17
ECI830
NCT06726148
P1/2RecruitingAdvanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors2802028-09-25
AcTFirst
NCT06855277
P3RecruitingProstate Cancer9402028-09-29 (+9 mo)
ALITHIOS
NCT03650114
P3Active, not recruitingRelapsing Multiple Sclerosis18822028-09-30 (+40 mo)
APPARENT
NCT05755386
P3RecruitingIC-MPGN1062028-10-27 (+34 mo)
Rapcabtagene autoleucel
NCT07048197
P1/2Active, not recruitingRheumatoid Arthritis (RA) and Sjögren's Disease (SjD)272028-11-01 (+5 mo)
ELIPSI
NCT07775924
P2RecruitingCutaneous Lichen Planus2592028-11-22
GHZ339
NCT06947993
P2RecruitingAtopic Dermatitis2242028-11-27
LTP
NCT06649110
P1/2RecruitingHealthy Volunteers, Pulmonary Arterial Hypertension2322028-11-29 (+28 mo)
rapcabtagene autoleucel
NCT06655896
P2Active, not recruitingScleroderma, Diffuse962028-11-30
NETTER-3
NCT06784752
P3RecruitingSomatostatin Receptor Positive (SSTR+); Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)2402028-12-08 (+6 mo)
DDY391
NCT07801495
P2RecruitingModerate to Severe Psoriatic Arthritis2202028-12-13
Arumakimig
NCT07748624
P2RecruitingVEXAS Syndrome1202028-12-26
QVM149
NCT05776927
P3RecruitingAsthma1882028-12-30 (+33 mo)
VAY2EXPLORE
NCT07421167
P2RecruitingPrimary Immune Thrombocytopenia (ITP); Primary Evans Syndrome (ES)1642029-01-18
Alpelisib
NCT06997588
P2RecruitingPIK3CA-related Overgrowth Spectrum (PROS)1402029-01-29 (+6 mo)
ASC4TARGET
NCT06514534
P2RecruitingChronic Myeloid Leukemia (CML)202029-02-17 (+3 mo)
DDY391
NCT07737743
P2RecruitingSjögren's Disease3442029-02-19
Remibrutinib
NCT07811869
P3RecruitingChronic Pruritus of Unknown Origin1802029-02-26
Rapcabtagene autoleucel
NCT06665256
P2Active, not recruitingIdiopathic Inflammatory Myopathies212029-03-09
NIO752
NCT07868328
P2Not yet recruitingProgressive Supranuclear Palsy; Corticobasal Degeneration482029-03-26
Remibrutinib
NCT07768371
P3RecruitingIgE-Mediated Food Allergy; Peanut Allergy5762029-03-30
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
NCT05739383
P3Active, not recruitingPrimary Prevention of Atherosclerotic Cardiovascular Disease140122029-04-16
Midostaurin
NCT03591510
P2Active, not recruitingFLT3-mutated Acute Myeloid Leukemia222029-05-18 (+85 mo)
Rapcabtagene autoleucel
NCT06868290
P2Active, not recruitingANCA Associated Vasculitis (AAV)1262029-06-07
KontRASt-R
NCT07468071
P1/2Active, not recruitingLocally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer; Advanced Solid Tumors Harboring the KRAS G12C Mutation252029-06-11
SPARKLE
NCT06439082
P3RecruitingSickle Cell Disease3542029-07-02 (+3 mo)
Votoplam
NCT06254482
P2Active, not recruitingHuntington Disease1442029-07-16 (+25 mo)
NIO752
NCT07498426
P3RecruitingProgressive Supranuclear Palsy Richardson Syndrome (PSP-RS)3002029-07-20
Remibrutinib oral treatment
NCT06846281
P3RecruitingRelapsing Multiple Sclerosis4002029-07-25 (-7 mo)
THALASSA
NCT07621809
P3RecruitingSjögren´s Disease5702029-08-15
FWY003
NCT07441642
P2RecruitingGeographic Atrophy Secondary to Age-related Macular Degeneration2722029-08-21
Adjuvant WIDER
NCT05827081
P3Active, not recruitingEarly Breast Cancer14662029-09-07 (-10 mo)
YTB323
NCT06704269
P1/2Active, not recruitingGeneralized Myasthenia Gravis152029-10-26 (+3 mo)
TulmiSTAR-01
NCT07206056
P1/2RecruitingProgressive Metastatic Castrate Resistant Prostate Cancer1882029-11-09
DDY391
NCT07923773
P2Not yet recruitingModerate to Severe Psoriatic Arthritis882029-12-12
Remibrutinib
NCT07700056
P3RecruitingChronic Pruritus of Unknown Origin1802029-12-19
Pelabresib
NCT06401356
P3RecruitingHematologic Malignancy; Solid Tumor502029-12-31 (+66 mo)
Pelacarsen (TQJ230)
NCT07517263
P3Active, not recruitingCardiovascular Disease and Lipoprotein(a)57002030-01-09
Tulmimetostat
NCT04104776
P1/2RecruitingAdvanced Solid Tumor; Diffuse Large B Cell Lymphoma3002030-02-27 (+50 mo)
Pelacarsen (TQJ230) 80mg
NCT05646381
P2RecruitingAortic Stenosis5022030-03-12 (+26 mo)
INVEST-HD
NCT07326709
P3RecruitingHuntington Disease7702030-04-02
NATALEE
NCT03701334
P3Active, not recruitingEarly Breast Cancer51012030-05-29 (+54 mo)
rapcabtagene autoleucel (YTB323)
NCT06675864
P1/2Active, not recruitingProgressive Multiple Sclerosis282030-06-14
iptacopan
NCT06994845
P3RecruitingPrimary Immunoglobulin A Nephropathy (IgAN)312030-06-28
SHIFT
NCT07146906
P2RecruitingImmunoglobulin A Nephropathy (IgAN)322030-07-12 (+3 mo)
rapcabtagene autoleucel (YTB323)
NCT06617793
P1/2Active, not recruitingRelapsing Multiple Sclerosis282030-08-07
PINNACLE-MI
NCT07938411
P3Not yet recruitingMyocardial Infarction100002030-10-22
REMASTER
NCT07225504
P3RecruitingSecondary Progressive Multiple Sclerosis (SPMS)12752030-12-03
LNP023
NCT04557462
P3RecruitingPrimary IgA Nephropathy5402030-12-04 (+30 mo)
Pelacarsen (TQJ230)
NCT06875973
P3Active, not recruitingAtherosclerotic Cardiovascular Disease5992030-12-08 (+35 mo)
LILAC-TIMI 76
NCT07739888
P3Not yet recruitingAtrial Fibrillation (AF)25002030-12-30
DJI136
NCT07564401
P1/2RecruitingExtensive-stage Small Cell Lung Cancer (ES-SCLC)802031-03-03
SPECTRUM
NCT05335876
P3Active, not recruitingSpinal Muscular Atrophy (SMA)202031-04-29 (-102 mo)
QCZ484
NCT07543120
P2RecruitingHypertension (HTN)3232031-05-07
GVV858
NCT07288359
P1/2RecruitingAdvanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors2052031-05-09
CYStem
NCT06910813
P1/2RecruitingNephropathic Cystinosis302031-05-28 (+9 mo)
zigakibart
NCT06858319
P3RecruitingKidney Diseases; Kidney Diseases, Chronic2202031-06-25
ADVANCE
NCT07498335
P3RecruitingBerger Disease; Bergers Disease282031-09-15
LNP023
NCT06934967
P3RecruitingParoxysmal Nocturnal Hemoglobinuria (PNH)122031-10-14
Remibrutinib
NCT07665437
P3RecruitingHidradenitis Suppurativa7102031-10-15
EPIK-RO
NCT07679269
P2Not yet recruitingPIK3CA-Related Overgrowth Spectrum (PROS); Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation)512032-03-23
V-PEDS-OLE
NCT05682378
P3RecruitingHeterozygous or Homozygous Familial Hypercholesterolemia1952032-03-25 (+52 mo)
Iptcaopan 200 mg
NCT05795140
P3RecruitingAtypical Hemolytic Uremic Syndrome652032-07-16 (+58 mo)
TulmiSTAR-02
NCT07190300
P1/2RecruitingMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)1812032-08-02 (+3 mo)
Remibrutinib
NCT07456891
P3RecruitingIndication of the Parent Protocol6502033-01-30
Asciminib single agent
NCT07354074
P2RecruitingChronic Myelogenous Leukemia; Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive502033-02-23
VAYHIT-P
NCT07660172
P2Not yet recruitingPrimary Immune Thrombocytopenia (ITP)362033-04-22
NEPTUNUS-Ext
NCT05985915
P3Active, not recruitingSjogrens Syndrome6122033-04-22 (+56 mo)
Asciminib Adult formulation
NCT07387926
P1/2RecruitingAcute Lymphoblastic Leukemia; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive502033-09-19
SIRIUS-SLE LTE
NCT06133972
P3RecruitingSystemic Lupus Erythematosus5502034-04-03 (+28 mo)
SIRIUS-LN ext
NCT06711887
P3RecruitingLupus Nephritis3482035-08-01 (+61 mo)
LNP023
NCT03955445
P3RecruitingC3 Glomerulopathy; Immune-complex-membranoproliferative Glomerulonephritis2252036-05-30
PAVO
NCT02445222
P3RecruitingLong Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program11052039-04-18 (+39 mo)